![]() |
|
| • |
Awarded $15 Million Procurement Contract from Canadian Department of National Defence for Oral TPOXX in October
|
| • |
Corporate Update Conference Call Today at 4:30 PM ET
|
|
($ in millions, except
per share amounts)
|
Three Months
Ended September 30
|
Nine Months
Ended September 30
|
||||||||||||||
|
2026
|
2025
|
2026
|
2025
|
|||||||||||||
|
Product sales (1)
|
$
|
0.2
|
$
|
0.9
|
$
|
41.6
|
$
|
85.8
|
||||||||
|
Total revenues (2)
|
$
|
1.3
|
$
|
2.6
|
$
|
48.6
|
$
|
90.8
|
||||||||
|
Operating (loss)/income(3) (4)
|
$
|
(6.5
|
)
|
$
|
(10.2
|
)
|
$
|
2.1
|
$
|
33.2
|
||||||
|
(Loss)/income before income taxes(3)
|
$
|
(5.5
|
)
|
$
|
(8.4
|
)
|
$
|
5.3
|
$
|
38.3
|
||||||
|
Net (loss)/income
|
$
|
(2.9
|
)
|
$
|
(6.4
|
)
|
$
|
6.1
|
$
|
28.7
|
||||||
|
Diluted (loss) / income per share
|
$
|
(0.04
|
)
|
$
|
(0.09
|
)
|
$
|
0.09
|
$
|
0.40
|
||||||
|
(1)
|
Includes supportive services related to product sales.
|
|
(2)
|
Includes research and development revenues.
|
|
(3)
|
Operating (loss)/income excludes, and (loss)/income before income taxes includes, other
income. Both line items exclude the impact of income taxes.
|
|
(4)
|
Differences in operating (loss)/income margin between periods reflect different product mixes in those periods.
|
![]() |
|
| • |
In October, the Canadian Department of National Defence (CDND) awarded a contract to SIGA for the procurement of oral
TPOXX. The contract provides for the purchase of up to approximately $15 million of oral TPOXX by March 31, 2031, of which approximately $9 million represents firm commitments over the first three years of the contract and approximately
$6 million is subject to option exercise by the CDND.
|
| • |
For the nine months ended September 30, 2026, the Company delivered approximately $13 million of oral TPOXX to two international customers.
|
| • |
For the nine months ended September 30, 2026, the Company delivered approximately $26
million of IV TPOXX to the U.S. Strategic National Stockpile (SNS) under the 19C contract, fulfilling the final procurement order under that contract.
|
![]() |
|
![]() |
|
|
September 30,
2026
|
December 31,
2025
|
|||||||
|
ASSETS
|
||||||||
|
Current assets
|
||||||||
|
Cash and cash equivalents
|
$
|
116,380,386
|
$
|
154,966,414
|
||||
|
Accounts receivable
|
2,016,213
|
3,263,736
|
||||||
|
Inventory
|
41,594,073
|
49,054,873
|
||||||
|
Prepaid expenses and other current assets
|
5,547,353
|
5,571,841
|
||||||
|
Total current assets
|
165,538,025
|
212,856,864
|
||||||
|
Property, plant and equipment, net
|
1,376,079
|
1,090,824
|
||||||
|
Deferred tax asset, net
|
4,706,158
|
4,428,519
|
||||||
|
Goodwill
|
898,334
|
898,334
|
||||||
|
Other assets
|
129,507
|
192,893
|
||||||
|
Total assets
|
$
|
172,648,103
|
$
|
219,467,434
|
||||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
|
Current liabilities
|
||||||||
|
Accounts payable
|
$
|
480,572
|
$
|
824,522
|
||||
|
Accrued expenses and other current liabilities
|
6,222,914
|
6,520,057
|
||||||
|
Deferred IV TPOXX® revenue
|
—
|
10,240,000
|
||||||
|
Income tax payable
|
34,123
|
408,000
|
||||||
|
Total current liabilities
|
6,737,609
|
17,992,579
|
||||||
|
Other liabilities
|
2,656,647
|
2,653,283
|
||||||
|
Total liabilities
|
9,394,256
|
20,645,862
|
||||||
|
Commitments and contingencies
|
||||||||
|
Stockholders’ equity
|
||||||||
|
Common stock ($.0001 par value, 600,000,000 shares authorized, 71,855,015 and 71,611,302, issued and
outstanding at September 30, 2026 and December 31, 2025, respectively)
|
7,185
|
7,161
|
||||||
|
Additional paid-in capital
|
244,109,230
|
241,885,214
|
||||||
|
Accumulated deficit
|
(80,862,568
|
)
|
(43,070,803
|
)
|
||||
|
Total stockholders’ equity
|
163,253,847
|
198,821,572
|
||||||
|
Total liabilities and stockholders’ equity
|
$
|
172,648,103
|
$
|
219,467,434
|
||||
![]() |
|
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
|
2026
|
2025
|
2026
|
2025
|
|||||||||||||
|
Revenues
|
||||||||||||||||
|
Product sales and supportive services
|
$
|
233,689
|
$
|
889,748
|
$
|
41,641,900
|
$
|
85,835,855
|
||||||||
|
Research and development
|
1,083,276
|
1,730,252
|
6,919,898
|
4,944,963
|
||||||||||||
|
Total revenues
|
1,316,965
|
2,620,000
|
48,561,798
|
90,780,818
|
||||||||||||
|
Operating expenses
|
||||||||||||||||
|
Cost of sales and supportive services
|
575,660
|
1,002,083
|
21,077,729
|
26,714,283
|
||||||||||||
|
Selling, general and administrative
|
4,621,909
|
4,786,511
|
14,443,914
|
15,949,749
|
||||||||||||
|
Research and development
|
2,639,444
|
7,053,985
|
10,975,788
|
14,914,895
|
||||||||||||
|
Total operating expenses
|
7,837,013
|
12,842,579
|
46,497,431
|
57,578,927
|
||||||||||||
|
Operating (loss)/income
|
(6,520,048
|
)
|
(10,222,579
|
)
|
2,064,367
|
33,201,891
|
||||||||||
|
Other income, net
|
1,037,470
|
1,866,693
|
3,261,847
|
5,143,981
|
||||||||||||
|
(Loss)/Income before income taxes
|
(5,482,578
|
)
|
(8,355,886
|
)
|
5,326,214
|
38,345,872
|
||||||||||
|
Benefit/(Provision) for income taxes
|
2,589,514
|
1,990,067
|
789,904
|
(9,636,811
|
)
|
|||||||||||
|
Net and comprehensive (loss)/income
|
$
|
(2,893,064
|
)
|
$
|
(6,365,819
|
)
|
$
|
6,116,118
|
$
|
28,709,061
|
||||||
|
Basic (loss)/income per share
|
$
|
(0.04
|
)
|
$
|
(0.09
|
)
|
$
|
0.09
|
$
|
0.40
|
||||||
|
Diluted (loss)/income per share
|
$
|
(0.04
|
)
|
$
|
(0.09
|
)
|
$
|
0.09
|
$
|
0.40
|
||||||
|
Weighted average shares outstanding: basic
|
71,849,132
|
71,604,956
|
71,751,272
|
71,499,984
|
||||||||||||
|
Weighted average shares outstanding: diluted
|
71,849,132
|
71,604,956
|
71,895,843
|
71,801,188
|
||||||||||||